Please login to the form below

Not currently logged in
Email:
Password:

Viread

This page shows the latest Viread news and features for those working in and with pharma, biotech and healthcare.

Gilead's Hepatitis B therapy Vemlidy granted EU approval

Gilead's Hepatitis B therapy Vemlidy granted EU approval

Gilead's Hepatitis B therapy Vemlidy granted EU approval. Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage. ... Vemlidy (tenofovir alafenamide, TAF) is a once-daily oral treatment, and produces a similar antiviral efficacy to

Latest news

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    The EMA advisors issued a positive opinion for Vemlidy (tenofovir alafenamide) after data from two phase III studies showed Vemlidy to be superior to its predecessor Viread (tenofovir disproxil) in both ... Due to TAF's greater plasma stability, Vemlidy

  • Prices of AZ and GSK drugs slashed in China Prices of AZ and GSK drugs slashed in China

    The reductions affect GlaxoSmithKline's hepatitis B and HIV therapy Viread (tenofovir), AstraZeneca's lung cancer drug Iressa (gefitinib) and Conmana (icotinib) - another lung cancer treatment made by Chinese firm Betta ... Pharmaceuticals. Viread's

  • Gilead boosts liver disease pipeline with $1.2bn acquisition Gilead boosts liver disease pipeline with $1.2bn acquisition

    Descovy (emtricitabine tenofovir alafenamide) can be paired with a range of third agents and is given at a dosage over 90% lower than Gilead's existing treatment Viread (tenofovir disoproxil fumarate).

  • Priority FDA review for new Gilead HCV combination therapy Priority FDA review for new Gilead HCV combination therapy

    The trials involved treatment-naïve and treatment-experienced adults with HBeAg-negative and HBeAg-positive chronic and showed that TAF was as effective as Gilead's older HBV therapy Viread (tenofovir

  • Gilead's HIV drug Genvoya cleared in EU Gilead's HIV drug Genvoya cleared in EU

    TAF is a novel targeted prodrug of tenofovir that has shown high antiviral activity similar to a dose less than one-tenth that of Gilead's Viread (tenofovir disoproxil fumarate, TDF).

More from news
Approximately 4 fully matching, plus 31 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics